Vertex Pharmaceuticals Inc. closed $47.49 short of its 52-week high ($510.64), which the company reached on August 1st.

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...

The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of ...

Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

Management is planning to accelerate growth by investing 20% more in its brands than last year. Kenvue may not be a fast ...

The studies are among a handful of pioneering trials using stem cells to treat diabetes, which affects close to half a ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

New analyses extend data on beneficial effects of ibezapolstat on the gut microbiomeConfirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic ...

Threekit, the leader in Visual Commerce, is further evolving a new era in sales with the launch of AI Guided Selling. The tool enables buyers to interact with an AI-powered agent to engage with their ...